In the high-end medical device industry, Daxing District mainly focuses on key areas such as cardio and cerebrovascular, orthopedics and surgery, enhances the research and development capabilities of high-value medical consumables, and actively develops high-end implanted and interventional products such as bone transplants, biological repair tablets, artificial spine and joints, nerve intervention, and artificial eardrums. It makes in vitro diagnostic technology products more convenient, easy and accurate, accelerates the research and development of new diagnostic reagents such as biochemical diagnosis and immunodiagnosis, develops biological information analysis software, and promotes the industrialization of detection and diagnostic instruments including genetic sequencing and molecular diagnostics. Meanwhile, it breaks through the constraints of core technologies and key components of high-end medical devices, improves independent innovation capabilities, accelerates the development of core technologies such as medical digital image collection and three-dimensional processing technology, improves the production capacity of key components for medical display screens and radiation protection, actively develops X-ray and ultrasound equipment, PET-CT and other high-performance diagnosis and treatment equipment, and cultivates a batch of domestically produced alternative benchmark products. It also accelerates the integrated development of new-generation information technologies such as 5G, big data, Internet of Things, and artificial intelligence with medicine-related health, and develops emerging industries such as telemedicine and wearable health equipment.

In the biopharmaceutical field, Daxing District mainly meets the drug needs of major diseases and infectious diseases, has a forward-looking layout of the frontier of biopharmaceutical innovation, and accurately positions the next-generation antibodies, vaccines, cell and gene therapy and other emerging tracks. It introduces and cultivates new antibody research and development teams, accelerates the research and development of next-generation antibody drugs such as bispecific antibodies and nanobodies, and promotes the industrialization of innovative achievements such as monoclonal antibodies. In addition, it supports the research, development and scale production of vaccine products such as bacterial vaccines, virus vaccines and polyvalent and multivalent combined vaccines, and strengthens the development of a new vaccine reserve development system. It promotes the industrial application of cell and gene therapy drugs and technologies, establishes key common technology platforms and supporting systems for cell culture, purification and culture media, etc., introduces CAR-T, UCAR-T and other anti-tumor T-cell immunotherapy innovative enterprises and carries out IPSC and other stem cell regenerative medicine research. In addition, it builds gene editing platforms, explores innovative applications of CRISPR gene editing technologies, and makes a forward-looking layout of small nucleic acid drugs, oncolytic viruses and other frontier fields.

In terms of innovative drugs, Daxing District increases investment in chemical drug research and development in response to the growing market demand for chemical drug preparations at home and abroad, focuses on accelerating the imitation of foreign off-patent drugs with high market potential and high clinical value, introduces a number of high-value-added generic drug enterprises and projects, promotes the consistency evaluation of generic drugs, and ensures the security of mature drug supplies. It actively promotes the research and development of innovative drugs, supports enterprises to increase investment in research and development, develop original and improved innovative drugs for major diseases such as tumors, cardiovascular and cerebrovascular diseases, and introduce innovative projects from high-quality pharmaceutical companies. In addition, it supports enterprises to introduce artificial intelligence to empower drug research and development, reduce the cycle and cost of research and development, and improve the development efficiency of drugs.

In the modern Chinese medicine industry, Daxing District actively promotes the development of classic Chinese medicine prescriptions, accelerates the modernization of the Chinese medicine industry, supports the transformation, upgrading and innovative research and development of stock enterprises, uses modern biotechnology such as supercritical fluid extraction and membrane separation to develop innovative products such as formula granules and Chinese patent medicines with clear effective ingredients and clear mechanism, increase the added value of the Chinese medicine industry and support the expansion of Chinese medicine into health foods, Chinese medicine

In line with the development trend of open and integrated "platform-based innovation mode" in the medicine-related health field, the medical innovation service industry in Daxing District focuses on the CXO platform, improves the overall innovation efficiency of the biomedical industry system, introduces professional service organizations such as CRO, and CMO/CDMO, and provides enterprises with one-stop solutions varying from new drug discovery, pre-clinical research and clinical services, process verification, pilot-scale transformation, commissioned production, commissioned inspection, and production system document drafting to improve the medicine-related

Daxing District gathers the National Institutes for Food and Drug Control, the highest national statutory inspection and arbitration institution for the quality of drugs and biological products, the domestic largest drug research institutions with the most output such as the Chinese Academy of Medical Sciences (the Institute of Materia Medica, Pathogen, Animal, and Biotechnology), and the Artemisinin Research Center of the China Academy of Chinese Medical Sciences, national administrations for the affairs including the analysis and treatment of animal epidemic, the prevention and control of major animal diseases and the quality and safety monitoring of livestock and poultry products, including the China Institute of Veterinary Drug Control and the China Animal Disease Control Center, as well as medical bases where the Institute of Materia Medica of China National Traditional Chinese Medicine Corporation, the Science and Technology Development Center of the Chinese Pharmaceutical Association, the Animal Experiment Center of the University for Science and Technology, Beijing, and the Beijing Animal Disease Prevention and Control Center have settled, and establishes a green channel for drug approval with the park.